Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
01 mars 2021 16h01 HE
|
Viela Bio
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients...
Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
25 févr. 2021 08h30 HE
|
Viela Bio
-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure...
Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
22 févr. 2021 07h00 HE
|
Viela Bio
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients...
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
10 nov. 2020 16h15 HE
|
Viela Bio
GAITHERSBURG, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
05 nov. 2020 16h01 HE
|
Viela Bio
-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted in...
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
02 nov. 2020 07h00 HE
|
Viela Bio
GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
03 sept. 2020 16h01 HE
|
Viela Bio
GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
12 août 2020 16h15 HE
|
Viela Bio
GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
05 août 2020 07h00 HE
|
Viela Bio
GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune...
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
11 juin 2020 17h45 HE
|
Viela Bio
GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNATM (inebilizumab-cdon) for the...